Company
Carigent is a privately held biopharmaceutical company located in New Haven, CT dedicated to the development of next generation therapeutics and diagnostic agents using a propriety drug delivery platform which is extremely versatile and robust. The platform allows for controlled release of therapeutic agents, specific targeting of therapy to a particular physiological site, tethering of surface ligands, and the ability to combine multiple agents into one vehicle made primarily from FDA approved materials. The technology is unique since it incorporates an unprecedented and extraordinarily high density of surface ligands into established, well-characterized, safe materials which allow:
- remarkable flexibility in targeting the drug delivery system for a variety of disease states and delivery routes
- ability to combine imaging agents with drug, and/or
- enhancement of in vivo circulation times
The exceptional density of tethering allows for combination of multiple surface ligands from both therapeutic and diagnostic fields and has the potential to enhance therapeutic effects to levels beyond that which can be achieved with surface modifications on other platforms.
The company started operations in 2007 with a team focused on generating a comprehensive product pipeline in multiple therapeutic areas including cancer treatment, antibody therapeutics, and siRNA delivery. Because of the flexibility and robust nature of the surface modification and controlled-release properties of the platform, collaborations with partners are a strong company focus. Our business strategy centers on the core technology of surface-modified, nanoparticle encapsulation of therapeutic agents where Carigent develops drug products both internally and in collaboration with pharmaceutical and biotechnology industry leaders, with the purpose of improving upon drugs known to be effective but limited by toxicities, as well as proprietary compounds. |
